Prevention of heart failure

Current Cardiology Reports

Volumn 4, Issue 3, 2002, Pages 194-199

  Horwich, Tamara B ^a   Fonarow, Gregg C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; TICLOPIDINE;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DISEASE COURSE; HEALTH BEHAVIOR; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY FAILURE; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; RISK FACTOR; SMOKING;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS; CORONARY ARTERIOSCLEROSIS; DIABETES COMPLICATIONS; DISEASE PROGRESSION; HEALTH BEHAVIOR; HEART FAILURE, CONGESTIVE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; KIDNEY FAILURE; PLATELET AGGREGATION INHIBITORS; PREVALENCE; RISK FACTORS; SMOKING; TICLOPIDINE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0036580764     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-002-0050-4     Document Type: Article

References (41)

1. American Heart Association: 2001 Heart and stroke statistical update. Dallas; American Heart Association: 2000.
2. He J, Ogden LG, Bazzano LA, et al.: Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 2001, 161:996-1002. This prospective cohort study follows 13,643 men and women without HF at baseline for an average of 19 years. Factors associated with development of HF are assigned relative risk and population attributable risk.
3. McKelvie RS, Benedict CR, Yusuf S: Prevention of congestive heart failure and management of asymptomatic left ventricular dysfunction. Br Med J 1999, 318:1400-1402.
4. Mann JFE, Gerstein HC, Pogue J, et al.: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001, 134:629-636.
5. Gerstein HC, Mann JFE, Yi Q, et al.: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001, 286:421-426. This subanalysis of the HOPE trial identifies microalbuminuria, defined by urine albumin to creatinine ratio2, as a novel risk factor for adverse cardiovascular outcomes, including HF hospitalization and all-cause mortality in both diabetics and nondiabetics.
6. Abramson J, Berger A, Krumholz HM, Vaccarino V: Depression and risk of heart failure among older persons with isolated systolic hypertension. Arch Intern Med 2001, 161:1725-1730.
7. McDonagh TA: Asymptomatic left ventricular dysfunction in the community. Curr Cardiol Rep 2000, 2:470-474.
8. McDonagh TA, Robb SD, Murdoch DR, et al.: Biochemical detection of left ventricular systolic dysfunction. Lancet 1998, 351:9-13.
9. The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992, 327:685-691.
10. Adams KF, Baughman KL, Dec WG, et al.: HFSA guidelines for management of patients with heart failure caused by patients with left ventricular systolic dysfunction: pharmacologic approaches. J Cardiac Fail 1999, 5:357-382.
11. Exner DV, Dries DL, Waclawiw MA, et al.: Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the studies of left ventricular dysfunction. J Am Coll Cardiol 1999, 33:916-23. This retrospective analysis of the SOLVD trial demonstrates that b-blocker therapy in patients with ALVD (the prevention trial) is independently associated with improved survival, less death from HF, and a lowered risk of the composite endpoint of death or hospitalization for HF.
12. Vantrimpont P, Rouleau JL, Wun C, et al.: Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the survival and ventricular enlargement (SAVE) study. J Am Coll Cardiol 1997, 29:229-236.
13. Dries DL, Exner DV, Domanski MJ, et al.: The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000, 35:681-689.
14. Cooper HA, Exner DV, Domanski MJ: Light-to-moderate alcohol consumption and prognosis in patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000, 35:1753-1759.
15. Suskin N, Sheth R, Negassa A, Yusuf S: Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction. J Am Coll Cardiol 2001, 37:1677-1682. A subanalysis of the SOLVD trial, this study finds that current smokers with LV dysfunction (asymptomatic or symptomatic) have significantly increased risk of HF hospitalization, MI, and all-cause mortality than current nonsmokers. Of importance, never-smokers and ex-smokers had similar risk profiles.
16. The Heart Outcomes Prevention Evaluation Study Investigators: Effects of angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000, 342:145-153. This important study expands the indication for ACE inhibitor therapy to all patients with known or suspected CAD. A prospective, randomized, placebo-controlled study, HOPE demonstrates significant reduction in risk of mortality, MI, and HF in patients with vascular disease or diabetes and one additional cardiac risk factor.
17. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494-502.
18. The CAPRICORN Investigators: Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomized trial. Lancet 2001, 357:1385-1390. This randomized, placebo-controlled trial evaluated carvedilol therapy in 1959 post-MI patients with ejection fraction ε 40% with or without symptoms of HF. Carvedilol therapy was significantly reduced all-cause mortality and nonfatal MI.
19. Wilhelmsen L, Rosengren A, Eriksson H, et al.: Heart failure in the general population of men: morbidity, risk factors and prognosis. J Intern Med 2001, 249:253-261.
20. Kannel WB, Belanger AJ: Epidemiology of heart failure. Am Heart J 1991, 121:951-957.
21. Kjekshus J, Pedersen TR, Olsson AG, et al.: The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Cardiac Fail 1997, 4:249-254.
22. Bauersachs J, Galuppo P, Fraccarollo D, et al.: Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme A reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 2001, 104:982-985.
23. Dechend R, Fiebeler A, Park J, et al.: Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Circulation 2001, 104:576-581.
24. Fonarow GC, Gawlinski A, Moughrabi S, et al.: Improved treatment of cardiovascular disease by implementation of a cardiac hospitalization atherosclerosis management program: CHAMP. Am J Cardiol 2001, 87:819-822.
25. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial. JAMA 2000, 283L:1967-1975. Data from the doxazosin and chlorthalidone arms of the large, randomized ALLHAT trial are presented, offering rationale for the early discontinuation of the doxazosin arm. In this trial, including patients with hypertension and one additional cardiac risk factor, doxazosin was associated with a significantly higher risk of HF, MI, angina, and stroke.
26. Brown MJ, Palmer CR, Castaigne A, et al.: Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: intervention as a goal in hypertension treatment (INSIGHT). Lancet 2000, 356:366-372.
27. Pahor M, Psaty BM, Aleterman MH, et al.: Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomized controlled trials. Lancet 2000, 356:1949-1954. This meta-analysis offers evidence of the disparity in cardiovascular risk reduction between different classes of antihypertensive medications. An analysis of nine randomized controlled hypertension trials from 1994 to 2000, this study reports that calcium channel-antagonists compared with other first-line antihypertensives are associated with higher risk of MI and HF.
28. Iribarren C, Karter AJ, Go AS, et al.: Glycemic control and heart failure among adult patients with diabetes. Circulation 2001, 103:2668-2673.
29. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998, 317:703-713.
30. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J 1998, 317:713-720.
31. UK Prospective Diabetes Study Group: Intensive blood-control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
32. UK Prospective Diabetes Study Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854-865.
33. Brenner BM, Cooper ME, De Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869. This randomized, double-blind study evaluated therapy with the angiotensin receptor blocker losartan to placebo in patients with type II diabetes and nephropathy, and found that losartan treatment was associated with significantly lower rates of HF and renal failure.
34. Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-recentor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Enl J Med 2001, 345:851-860.
35. Abramson JL, Williams SA, Krumholz HM, Vaccarino V: Moderate alcohol consumption and risk of heart failure among older persons. JAMA 2001, 285:1971-1977.
36. Zannad F, Alla F, Dousset B, et al.: Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. Circulation 2000, 102:2700-2706.
37. Sakata Y, Masuyama T, Yamamoto K, et al.: Calcineurin inhibitor attenuates left ventricular hypertrophy, leading to prevention of heart failure in hypertensive rats. Circulation 2000, 102:2269-2275.
38. Creemers EEJM, Cleutjens JPM, Smits JFM, et al.: Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res, 2001, 89:201-210.
39. Konertz W, Kleber FX, Dush S, et al.: Initial efficacy trends with the acorn cardiac support device in patients with advanced heart failure [abstract]. J Am Coll Cardiol 2001, 143A.
40. Mensche P, Vilquin JT, Desnos M, et al.: Early results of autologous skeletal myoblast transplantation in patients with severe ischemic heart failure. Circulation 2001, 104:II-598.
41. Lau CP, Yu CM, Chau E, et al.: Reversal of left ventricular remodeling by synchronous biventricular pacing in heart failure. Pacing Clin Electrophysiol 2000, 23:1722-1725.